Shri Ahimsa Naturals Limited (NSE SME)
Mar 25, 2025 - Mar 27, 2025
| Price | ₹113 - ₹119 |
| Premium | ₹15 |
|---|---|
| Lot size | 1200 |
| Allotment | Mar 28, 2025 |
| Listing | Apr 2, 2025 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 1200 | 142800 | 1735 |
| HNI | 2 | 2400 | 285600 | 737 |
Last updated on 27-Mar-2025 18:19:02
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 1170000 | 24838800 | 21.23 |
| NIB | 884400 | 161686800 | 182.82 |
| RETAIL | 2082000 | 72867600 | 35 |
| Total | 4136400 | 259393200 | 62.71 |
| Application Wise Breakup | |
|---|---|
| Category | App. Received |
| QIB | 35 |
| NIB | 5465 |
| RETAIL | 60723 |
| Total | 66223 |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIB | 13.92 | 295.58 | 21.23 |
| NIB | 10.52 | 1924.07 | 182.82 |
| RETAIL | 24.78 | 867.12 | 35 |
| Total | 49.22 | 3086.78 | 62.71 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹3.4 | @8% ₹3.9 | @9% ₹4.4 | @10% ₹4.8 | @11% ₹5.3 | @12% ₹5.8 |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹29.2 | @8% ₹33.4 | @9% ₹37.6 | @10% ₹41.7 | @11% ₹45.9 | @12% ₹50.1 |
IPO Reservation
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| Retail | 33.57% | 2082000 |
| HNI | 14.26% | 884400 |
| Anchor | 28.28% | 1754400 |
| QIB | 18.86% | 1170000 |
| Market Maker | 5.03% | 312000 |
| Total | 100% | 6202800 |
Shri Ahimsa Naturals IPO Details
| Issue Size | 62,02,800 shares (aggregating up to ₹73.81 Cr) |
| Fresh Issue | 42,03,600 shares (aggregating up to ₹50.02 Cr) |
| Offer for Sale | 19,99,200 shares of ₹10 (aggregating up to ₹23.79 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 1,91,26,500 shares |
| Share Holding Post Issue | 2,33,30,100 shares |
| Market Maker Portion | 3,12,000 shares |
| Market Maker | Choice Equity Broking |
Key Performance Indicator (KPI)
| KPI | Sep-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 9.78% | 22.25% | 58.58% |
| ROCE | 12.59% | 25.69% | 72.46% |
| RONW | 9.78% | 22.25% | 58.58% |
| D/E | -0.02 | 0.07 | -0.09 |
| EPS (basic) | 5.25 | 10.19 | 20.85 |
| P/E Pre IPO | 12.19 | ||
| P/E Post IPO | 14.25 |
Company Financials In Crores
| Period Ended | Sep-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Assets | 111 | 103 | 74 | 40 |
| Revenue | 41 | 79 | 106 | 59 |
| Profit After Tax | 10 | 19 | 38 | 11 |
| Net Worth | 100 | 84 | 65 | 27 |
| Reserves and Surplus | 81 | 66 | 60 | 22 |
| Total Borrowing | 5 | 14 | 3 | 6 |
About Company
Incorporated in 1990, Shri Ahimsa Naturals Limited specializes in extracting and manufacturing Caffeine Anhydrous, Green Coffee Bean Extracts, and Crude Caffeine, along with trading other herbal extracts. The company's products cater to industries such as food & beverage, nutraceuticals, cosmetics, and pharmaceuticals due to their various health benefits. Its product portfolio includes Natural Caffeine, extracted from coffee and tea seeds, widely used in energy drinks, soft drinks, cosmetics, and pharmaceuticals, and Green Coffee Bean Extract, sourced from unroasted coffee seeds, known for its antioxidant properties and potential weight loss benefits. The company exports to multiple international markets, including the USA, Germany, South Korea, the UK, and Thailand. For the period ending September 30, 2024, the company reported export revenues of ₹3,530.91 lakhs, while its export revenues for Fiscal 2023 and Fiscal 2022 stood at ₹7,463.71 lakhs and ₹5,633.50 lakhs, respectively, reaching ₹9,988.01 lakhs in the highest fiscal year. The company's manufacturing unit in Jaipur, Rajasthan, adheres to global quality and safety standards, including ISO 9001:2015, ISO 22000:2018, ISO 45001:2018, ISO 14001:2015, HACCP, and GMP, ensuring superior quality production. As of March 2025, the company employed approximately 80 employees.
Experienced Leadership – Led by a seasoned team with deep industry expertise, driving strategic growth and innovation.
Advanced Manufacturing & R&D – A technology-driven production facility in Jaipur, Rajasthan, ensuring high-quality products and continuous improvement.
Strong Client Relationships – Established long-term partnerships with global clients across the food & beverage, nutraceuticals, cosmetics, and pharmaceutical industries.
Project Implementation Risks – The company's planned investment of ₹3,500 lakhs in its wholly owned subsidiary, Shri Ahimsa Healthcare Private Limited, for setting up a manufacturing unit is subject to potential delays, cost overruns, and dependency on Government approvals, which could impact operations and financial performance.
Audit Qualifications – The Statutory Auditors have included certain qualifications in their audit reports for the half-year ended September 30, 2024, and the fiscal years 2024, 2023, and 2022, which may raise concerns about financial reporting and compliance.
Vendor & Supply Chain Dependencies – Delays in procuring machinery, equipment, or completing civil and related works for the new manufacturing unit could disrupt expansion plans, leading to increased costs and operational setbacks.
Phone: +91-44-28460390
Email: info@shriahimsa.com
Website: https://ipo.cameoindia.com/